A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
Top Cited Papers
Open Access
- 11 August 2014
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 111 (38), 13817-13821
- https://doi.org/10.1073/pnas.1408124111
Abstract
The recent success of antibody–drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents. Here, we determined the high-resolution crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer. We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules. We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184. Consistent with biochemical and mutagenesis data, we found that the two compounds bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands. Our results delineate a distinct molecular mechanism of action for the inhibition of microtubule assembly by clinically relevant agents. They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.Keywords
This publication has 34 references indexed in Scilit:
- Antibody–drug conjugatesNature Reviews Drug Discovery, 2013
- Template-free 13-protofilament microtubule–MAP assembly visualized at 8 Å resolutionThe Journal of cell biology, 2010
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to MicrotubulesMolecular Cancer Therapeutics, 2010
- Microtubule-binding agents: a dynamic field of cancer therapeuticsNature Reviews Drug Discovery, 2010
- Structural insight into the inhibition of tubulin by vinca domain peptide ligandsEMBO Reports, 2008
- Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular ProcessingCancer Research, 2006
- Refined structure of αβ-tubulin at 3.5 Å resolution 1 1Edited by I. A. WilsonJournal of Molecular Biology, 2001
- Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin a, dolastatins 10 and 15 and halichondrin BPharmacology & Therapeutics, 1992
- Rhizoxin binding to tubulin at the maytansine-binding siteBiochimica et Biophysica Acta (BBA) - General Subjects, 1987
- Binding of maytansine to rat brain tubulinBiochemical and Biophysical Research Communications, 1976